Vitamin D3 Scientific References and Clinical Study Library

Vitamin D3 Scientific References: A Curated Clinical Study Library

Anyone researching vitamin D3 (cholecalciferol) quickly meets conflicting headlines. This page collects vitamin D3 scientific references in one place, grouped by study type so you can see how strong each kind of evidence is. Each entry has a one-line note on what it contributes, and none is presented as proof that a supplement cures or prevents disease. Use it to find primary sources and to judge claims critically.

Medical disclaimer: This page is educational and is not medical advice. Consult a qualified healthcare professional before starting, changing, or stopping any supplement.

1. How This Vitamin D3 Clinical Study Library Is Organized

The sections follow a rough evidence hierarchy for human questions: systematic reviews, meta-analyses, and randomized controlled trials (RCTs) first, then observational studies. Pharmacokinetic, safety, mechanistic, and preclinical work follows, because these explain how vitamin D3 behaves rather than whether it improves outcomes.

Three ground rules apply:

• Inclusion: I selected widely cited, peer-reviewed papers and major official documents that I am confident exist as cited. This is a curated sample, not an exhaustive database.
• No invented details: Where I could not confirm a DOI from memory, I have not listed one. Section 11 explains how to retrieve DOIs and PubMed records by title.
• Verify before relying: I did not run a live database search while writing this page. Check volume and page numbers against PubMed or the publisher before citing them formally.

A note on reading the evidence: established findings come from consistent, well-designed trials or reviews. Uncertain findings come from mixed or small studies. Hypotheses come mostly from mechanistic or animal work.

2. Systematic Reviews and Guidance Documents

Systematic reviews follow a predefined, reproducible method to find and appraise all relevant studies.

• Bjelakovic G, et al. (2014). Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev, CD007470. Found no strong signal for or against mortality benefit, with some signal for vitamin D3 specifically.
• Marcinowska-Suchowierska E, et al. (2018). Vitamin D toxicity: a clinical perspective. Front Endocrinol 9:550. Reviews causes, mechanisms, and management of hypervitaminosis D.
• Galior K, et al. (2018). Development of vitamin D toxicity from overcorrection of vitamin D deficiency: a review of case reports. Nutrients 10:953. Summarizes case reports of toxicity linked to dosing errors.
• Demay MB, et al. (2024). Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 109(8):1907–1947. Evidence-based guidance for people without established indications for vitamin D.

3. Meta-Analyses

Meta-analyses statistically pool results from several trials. They are only as good as the trials they combine.

• Bolland MJ, et al. (2014). The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2(4):307–320. Reported little effect on these outcomes in the pooled trials.
• Zhang Y, et al. (2019). Association between vitamin D supplementation and mortality: systematic review and meta-analysis. BMJ 366:l4673. Found no overall reduction in all-cause mortality; some analyses suggested a possible small cancer-mortality effect, which remains uncertain.
• Martineau AR, et al. (2017). Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ 356:i6583. Found a modest overall protective effect, concentrated in people with low baseline levels. Later trials have been less consistent, so this remains debated.
• Tripkovic L, et al. (2012). Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr 95:1357–1364. Found D3 raised 25(OH)D more effectively than D2.

4. Randomized Controlled Trials

RCTs are the strongest design for testing whether a supplement causes an outcome, but each answers a narrow question about a specific population and dose.

• Manson JE, et al. (2019), VITAL. N Engl J Med 380:33–44. Vitamin D3 did not significantly reduce invasive cancer or major cardiovascular events in a general population of older adults.
• LeBoff MS, et al. (2022), VITAL bone health. N Engl J Med 387:299–309. Supplementation did not reduce fractures in generally healthy midlife and older adults not selected for low vitamin D.
• Pittas AG, et al. (2019), D2d. N Engl J Med 381:520–530. In adults with prediabetes, vitamin D3 did not significantly reduce progression to diabetes in the primary analysis.
• Scragg R, et al. (2017), ViDA. JAMA Cardiol 2(6):608–616. Monthly high-dose vitamin D did not reduce cardiovascular disease in older adults.
• Neale RE, et al. (2022), D-Health. Lancet Diabetes Endocrinol 10:120–128. Monthly vitamin D did not reduce overall mortality in older Australians.
• Sanders KM, et al. (2010). JAMA 303(18):1815–1822. A once-yearly very high dose was associated with more falls and fractures in older women.
• Burt LA, et al. (2019). JAMA 322(8):736–745. Daily doses of 400, 4,000, or 10,000 IU for three years; higher doses did not improve bone density and the highest dose was linked to modest decreases.

5. Observational Human Studies

Observational studies can reveal associations but cannot prove cause. Illness can itself lower 25(OH)D, which makes reverse causation a persistent problem.

• Afzal S, et al. (2014). Genetically low vitamin D concentrations and increased mortality: Mendelian randomisation analysis in three large cohorts. BMJ 349:g6330. Genetic evidence linking lower vitamin D to higher mortality, a hypothesis-generating finding.
• Mokry LE, et al. (2015). Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. PLoS Med 12:e1001866. Genetic evidence suggesting low vitamin D may raise multiple sclerosis risk; supplementation trials are needed to test this.
• Jackson RD, et al. (2006), Women’s Health Initiative. N Engl J Med 354:669–683. Calcium plus vitamin D did not substantially reduce hip fracture, and kidney stone risk was modestly higher.

Mendelian randomization uses inherited genetic variants as a quasi-experimental tool. It reduces some confounding but has its own assumptions.

6. Pharmacokinetic Studies

These papers describe how vitamin D3 is absorbed, converted, and cleared.

• Heaney RP, et al. (2003). Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77:204–210. A classic dose-response study of how daily D3 intake changes 25(OH)D.
• Tripkovic L, et al. (2012). See Section 3, which also informs comparative pharmacokinetics.
• Christakos S, et al. (2016). Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev 96:365–408. A comprehensive review of metabolism, including liver conversion to 25(OH)D and kidney conversion to 1,25-dihydroxyvitamin D.

Established: 25(OH)D is the standard marker of status, and it has a long half-life (weeks), so levels change slowly.

7. Safety and Toxicology Studies

• Vieth R (1999). Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 69:842–856. An influential analysis arguing for higher upper limits; its conclusions remain debated.
• Hathcock JN, et al. (2007). Risk assessment for vitamin D. Am J Clin Nutr 85:6–18. Basis for risk assessment of upper intake levels.
• Billington EO, et al. (2020). Safety of high-dose vitamin D supplementation: secondary analysis of a randomized controlled trial. J Clin Endocrinol Metab 105(4):dgz212. More hypercalciuria and hypercalcemia at higher doses.
• Marcinowska-Suchowierska E, et al. (2018) and Galior K, et al. (2018). See Section 2.
• Schlingmann KP, et al. (2011). Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 365:410–421. Explains inherited sensitivity to vitamin D in some infants.

8. Mechanistic Studies

Mechanistic papers explain biology; they do not show clinical benefit.

• Holick MF (2007). Vitamin D deficiency. N Engl J Med 357:266–281. A widely read clinical review of vitamin D physiology and deficiency.
• Bikle DD (2014). Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 21:319–329. Reviews the vitamin D receptor and gene regulation.
• Christakos S, et al. (2016). See Section 6.

Established: vitamin D regulates calcium and phosphate balance through the vitamin D receptor. Hypothesis: effects on immunity, cell growth, and metabolism seen in laboratory settings may or may not translate into clinical outcomes.

9. Preclinical Studies

Animal and cell studies guide hypotheses but frequently fail to predict human results.

• Li YC, et al. (1997). Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci USA 94:9831–9835. Mice lacking the receptor develop rickets-like disease.
• Panda DK, et al. (2001). Targeted ablation of the 25-hydroxyvitamin D 1α-hydroxylase enzyme. Proc Natl Acad Sci USA 98:7498–7503. Showed the importance of activating vitamin D for mineral balance.

Rodent doses, diets, and physiology differ from human supplementation, so these findings should be treated as supporting biology only.

10. Study Table: Year, Design, Population, and Dose

Where I wrote “verify,” the exact regimen should be taken from the original paper rather than from this table.

11. DOI, PubMed, and Official Links

I have deliberately not typed DOIs from memory, because a single wrong character produces a broken or incorrect link. Use these reliable routes:

• PubMed: https://pubmed.ncbi.nlm.nih.gov/ — paste the paper title in quotation marks. Each record lists the DOI.
• Cochrane Library: https://www.cochranelibrary.com/ — for Cochrane reviews.
• ClinicalTrials.gov: https://clinicaltrials.gov/ — VITAL is registered as NCT01169259 and D2d as NCT01942694.
• NIH Office of Dietary Supplements, Vitamin D fact sheet for health professionals: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
• National Academies Press: search “Dietary Reference Intakes for Calcium and Vitamin D” (2011).
• European Food Safety Authority: https://www.efsa.europa.eu/ — search for the vitamin D tolerable upper intake level opinion (2023).
• Endocrine Society: https://www.endocrine.org/ — for the 2024 guideline.

To confirm a citation, find it in PubMed, compare authors, journal, year, volume, and pages, and then copy the DOI from the record.

Editorial note: SEO targets here are editorial guidance and do not guarantee any search ranking.